Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C24H31N3O |
| Molecular Weight | 377.5224 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CC1=CC=CC=C1)N(C)CC2=C(C(C)C)C(=O)N(N2C)C3=CC=CC=C3
InChI
InChIKey=GNUXVOXXWGNPIV-UHFFFAOYSA-N
InChI=1S/C24H31N3O/c1-18(2)23-22(17-25(4)19(3)16-20-12-8-6-9-13-20)26(5)27(24(23)28)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3
| Molecular Formula | C24H31N3O |
| Molecular Weight | 377.5224 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Famprofazone, a nonsteroidal anti-inflammatory agent, is found in a multi-ingredient medication (Gewodin) used for pain relief. It is available over-the-counter in Taiwan. Famprofazone transforms to methamphetamine (MA) and amphetamine (AM) following administration, which is responsible for the side effects of the drug. For example, famprofazone user might be interpreted as an illicit MA abuser in Taiwan because the user's urine tested positive for MA.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14607003 |
Palliative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Famprofazone use can be misinterpreted as methamphetamine abuse. | 2010-07-29 |
|
| Famprofazone as the source of methamphetamine and amphetamine in urine specimen collected during sport competition. | 2007-03 |
|
| Metabolic profile of famprofazone following multidose administration. | 2004-09 |
|
| Metabolic profile of amphetamine and methamphetamine following administration of the drug famprofazone. | 2003-10 |
|
| Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. | 2002-05 |
|
| Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. | 2002-04 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20663288
25 mg once per day
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:14:15 GMT 2025
by
admin
on
Mon Mar 31 18:14:15 GMT 2025
|
| Record UNII |
HN0NCX453C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
245-284-9
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
1130
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
759244
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
22881-35-2
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
Famprofazone
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
HN0NCX453C
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
DTXSID3045435
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
C65616
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
3326
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
C076013
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
CHEMBL1475693
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
SUB07506MIG
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
100000081760
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY | |||
|
2645
Created by
admin on Mon Mar 31 18:14:15 GMT 2025 , Edited by admin on Mon Mar 31 18:14:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |